HEPATITIS B TREATMENT VACCINE BASED ON INACTIVATED WHOLE RECOMBINANT HANSENULA CELL WHICH EXPRESSES HBSAG AND HBCAG

• 收藏
• 分享

专利权人:

WANG; Hemu

发明人:

WANG, Hemu,WANG, Changhua,YANG, Jun

申请号：

SG11201808267S

公开号：

SG11201808267SA

申请日:

2017.03.16

申请国别(地区):

SG

年份:

2018

代理人:

摘要：

Provided is a hepatitis B treatment vaccine based on an inactivated whole recombinant Hansenula cell which expresses HBsAg and HBcAg. An HBsAgVLP and an HBcAgVLP expressed in the recombinant Hansenula cell are used as antigens, the amino acid sequence of the HBsAg expressed by the recombinant Hansenula contains a total of 19 CTL epitopes, the amino acid sequence of the HBcAg expressed by the recombinant Hansenula contains a total of 19 CTL epitopes, and the inactivated whole recombinant Hansenula cell is used as an adjuvant.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/